Solim Health

Solim Health uses AI-powered memory therapy to slow cognitive decline and recreate meaningful memories for people living with dementia.

In its first week of launch, Solim Health generated strong early traction, reaching over 500,000 views across TikTok and Meta, 60,000 website visits, and acquiring 1,200 users with 100 booked therapy sessions. The company also secured a letter of intent (LOI) from a memory care facility worth $100,000 in annual recurring revenue (ARR) and began demos with four senior living providers representing an additional $200,000 ARR opportunity at a 50% conversion rate.

Solim Health targets a broad and growing market centered on cognitive health, aging, and emotional wellness. Its primary customer segment includes individuals living with dementia or mild cognitive impairment (MCI), along with their families and caregivers, who are actively seeking affordable, non-pharmaceutical therapies to slow cognitive decline and preserve identity. On the B2B side, Solim partners with memory care facilities, senior living providers, and healthcare organizations that integrate Solim’s telehealth therapy into their care programs to improve patient outcomes and reduce costs.

Beyond dementia care, Solim Health also serves adjacent markets such as palliative care, grief therapy, and proactive aging, where memory preservation and emotional reconnection provide significant value. The total addressable market (TAM) in the U.S. is estimated at $80 billion, with a $15 billion serviceable market (SAM) and a projected $1 billion obtainable market (SOM) within five years — representing roughly 8% market penetration. With over 45 million potential users across dementia, MCI, and related use cases, Solim Health is positioned to become a category leader in digital memory therapy and cognitive wellness.

Dementia and mild cognitive impairment affect over 20 million Americans and cost more than $390 billion annually across Medicare, Medicaid, and private payors. Current treatments like Lecanemab offer limited benefits, focusing on moderate to late stages while costing over $40,000 a year and carrying serious health risks such as brain swelling and bleeding. Patients and families overwhelmingly want to improve memory, preserve identity, slow disease progression, and reduce the financial burden of care — yet memory restoration and early cognitive interventions remain largely unaddressed.

Solim Health addresses this critical gap with an AI-powered memory therapy and reconstruction platform that delivers safe, effective, and affordable early-stage interventions for dementia. Clinically validated through research involving over 3,100 participants, Solim’s therapy is 95% cheaper than drug-based treatments and can delay progression by three to five years. Beyond dementia, the platform extends to grief support, palliative care, and proactive aging, representing an $80 billion market opportunity. By combining clinical rigor with advanced AI, Solim Health is positioned to become the first-line, non-pharmaceutical therapy for cognitive preservation and emotional well-being.

Solim Health currently offers a suite of complementary products designed to serve patients, caregivers, and payors. Its telehealth dementia therapy delivers nurse-led reminiscence therapy validated by research across more than 3,100 participants. The GenAI Memory Reconstruction platform enables users to transform personal stories and photos into lifelike digital memory scenes, helping preserve emotional connection and cognitive engagement. Additionally, Solim provides AI-based memory assessments and algorithms that detect fading memories, personalize therapy, and monitor cognitive change over time. Together, these offerings form an end-to-end, non-pharmaceutical solution for slowing cognitive decline and rebuilding meaningful memories.

The competitive landscape for Solim Health shows a large but fragmented market in which no single company currently leads in digital memory therapy. Competitors today tend to cluster into three main areas:

Telehealth behavioral therapy platforms that offer generalized cognitive or psychological support (e.g., Talkspace, BetterHelp) but do not focus specifically on dementia or memory restoration.

Dementia screening and monitoring solutions that provide cognitive assessments or tracking tools (e.g., Altoida, Neurotrack, Linus Health) but lack therapeutic interventions or emotional engagement components.

Generative AI and media platforms that create personalized digital experiences (e.g., Replika, HeyGen, D-ID) yet have no clinical or dementia-specific applications.

In contrast, Solim Health uniquely combines all three domains — clinical-grade telehealth therapy, continuous dementia monitoring, and generative AI–driven memory reconstruction — into a single, scalable platform. It is currently the only company delivering memory care through online reminiscence therapy at scale, capable of both slowing cognitive decline and digitally rebuilding patients’ core memories.

Because incumbents in behavioral health and digital therapeutics are focused on broader mental health or diagnostic use cases, they are more likely to partner with Solim Health than compete directly. This gives Solim a first-mover advantage in the emerging AI-powered memory therapy market, positioning it as the category creator with significant defensibility and partnership potential.

Solim Health’s advantage lies in its ability to bridge the gap between clinical care and emotional memory restoration through an integrated, AI-powered platform. Unlike conventional dementia treatments or digital health tools that focus solely on diagnostics or symptom management, Solim combines validated therapy, generative AI, and real-time monitoring to deliver measurable cognitive and emotional benefits.

Key differentiators include:

First-Mover in AI Memory Therapy: Solim Health is the first company to deliver large-scale, telehealth-based reminiscence therapy enhanced by generative AI, allowing users to digitally recreate and store their core memories.

Clinically Validated and Non-Pharmaceutical: The therapy model is backed by research involving more than 3,100 participants, offering proven cognitive benefits without the risks and side effects of pharmaceutical interventions.

Cost-Effective and Accessible: At 95% lower cost than drug-based therapies, Solim’s model provides early intervention and continuous support that’s affordable for families, facilities, and payors.

Comprehensive Platform: Solim integrates telehealth therapy, AI-based assessments, and memory reconstruction into a seamless care experience — unlike competitors who specialize in only one of these areas.

Data-Driven Cognitive Insights: Through continuous monitoring and memory data analytics, Solim can detect fading memories, personalize therapy, and track disease progression — creating a feedback loop that strengthens both outcomes and clinical value.

Strategic Market Positioning: By serving both B2C (families and individuals) and B2B (memory care facilities, senior living providers, and health organizations), Solim captures a wider market footprint and builds defensibility through institutional partnerships.

Together, these strengths make Solim Health the only platform capable of offering personalized, AI-driven, clinically guided memory therapy that both slows cognitive decline and restores emotional connection — setting it apart as a category-defining solution in dementia care.

Solim Health generates revenue through a hybrid B2C and B2B model designed for scalability and recurring income. On the consumer side, the company offers a monthly subscription for telehealth-based memory therapy priced around $100 per month, supplemented by add-on products such as AI memory reconstruction packs ($30 each) and cognitive assessments ($10 each). These offerings allow personalization and ongoing engagement while maintaining strong unit economics. On the enterprise side, Solim partners with memory care facilities, senior living providers, and healthcare organizations, generating recurring B2B revenue through licensing and integration contracts. Additional long-term opportunities include payer reimbursement, data-driven insights, and clinical research collaborations.

The company’s cost structure is primarily driven by technology development, clinical delivery, and marketing. Key expenses include compensation for nurses and therapists delivering telehealth sessions, engineering and AI development, data storage and infrastructure, visual content design, and user acquisition through marketing and brand awareness campaigns. Supporting costs include R&D, legal and regulatory compliance, insurance, and Medicare-related setup. With a digital-first delivery model and scalable subscription base, Solim Health projects gross margins of 70–90%, allowing sustainable growth as user adoption expands.

ChatGPT said:

Solim Health operates a hybrid B2B and B2C subscription-based business model designed for scalability and recurring revenue. On the B2C side, individuals and families can access Solim’s memory therapy platform through a monthly subscription priced at approximately $100 per month, with add-on offerings such as custom memory reconstruction packs ($30) and AI-based cognitive assessments ($10). This structure allows customers to personalize their therapy experience while generating high-margin, predictable income for Solim.

On the B2B side, Solim partners with memory care facilities, senior living providers, and healthcare organizations, licensing its platform and therapy services to integrate directly into existing care programs. These partnerships create long-term contracts and recurring revenue streams while reducing the financial burden of traditional dementia care for payors and providers.

Overall, Solim Health’s model combines clinical-grade therapy, AI-driven personalization, and affordable digital delivery to capture value across multiple channels. With projected gross margins of 70–90%, the company’s scalable subscription and licensing structure positions it for strong unit economics and rapid expansion across both consumer and institutional markets.

Based on the deck, Solim Health plans to use the $1.2 million raise to support rapid scaling over the next two years, with a focus on product development, clinical validation, and market expansion. The funds will be allocated across several key areas:

R&D and Technology Development: Advancing the AI platform, memory reconstruction capabilities, and clinical data systems.

Talent Acquisition: Hiring additional engineers, visual designers, nurses, and therapists to expand both the technical and clinical teams.

Clinical Setup: Supporting partnerships, pilot programs, and regulatory preparation for broader clinical integration.

Marketing and Brand Awareness: Driving user acquisition through digital campaigns and expanding B2B outreach to senior living and care facilities.

Legal, Insurance, and Medicare Compliance: Ensuring operational readiness for healthcare partnerships and payer relationships.

Overall, the investment will fund the next stage of Solim Health’s growth — from validated pilot to large-scale commercialization — while maintaining projected gross margins of 70–90%.

Raising $800K at a $8M post money SAFE

Solim Health faces several key risks as it scales its AI-powered memory therapy platform. Clinically, while reminiscence therapy is supported by research, the company must demonstrate large-scale, measurable outcomes specific to its technology to gain widespread medical credibility and payer adoption. Market adoption also poses a challenge, as dementia care is traditionally conservative, and both families and care providers may take time to trust and adopt new digital interventions. Technologically, Solim’s reliance on AI and the storage of deeply personal memory data introduces privacy, security, and ethical risks that require strict compliance with HIPAA standards and transparent data practices.

The company also faces potential competitive pressures from larger healthcare or technology incumbents that could enter the digital dementia therapy space with greater resources. Additionally, reimbursement risk remains a factor, as scaling B2B partnerships and payer integrations will depend on proving clear clinical and economic value. Finally, as an early-stage company operating across healthcare, AI, and consumer engagement, Solim’s success depends on its ability to attract and retain top talent in technical, clinical, and operational roles. Managing these risks effectively will be essential to maintaining trust, regulatory alignment, and sustainable growth.

ChatGPT said:

During our time at Techstars, we built a strong network of mentors, industry experts, and healthcare partners who helped accelerate our growth. Through the program, we successfully ran a 100-person pilot to validate our therapy model and gather key user insights, which directly informed product improvements and engagement strategies. We also used this period to develop and refine our commercial product, transitioning from prototype to a scalable platform ready for market launch.

Solim Health was selected from over 2,000 startup applicants to join Techstars, receiving a $120,000 investment to help build the future of AI in healthcare. This recognition reflects both the strength of our vision and the transformative potential of our technology in redefining how memory therapy and cognitive care are delivered.